AbbVie cuts 2024 profit forecast on R&D expenses

(Reuters) -AbbVie lowered its 2024 adjusted profit forecast on Wednesday, citing $937 million in milestones, and research and development expenses related to acquisitions. The drugmaker has been focusing on expanding its pipeline since its blockbuster arthritis drug, Humira, lost patent protection last year. The company expects annual adjusted profit in the range of $10.61 to…

Read More

    Fed’s Goolsbee sees warnings signs on real economy

    (Reuters) – Chicago Federal Reserve Bank President Austan Goolsbee on Tuesday said he sees some “warning signs” of weakening in the economy, adding that the U.S. central bank’s goal is to get inflation down without stressing the labor market. “I see some warning signs the real economy is weakening,” Goolsbee told CNBC in an interview on…

    Read More

      Spirit Aero to be broken up as Boeing agrees to $4.7 billion stock deal

      By Tim Hepher, Shivani Tanna and Mike Stone (Reuters) -Boeing agreed to buy back Spirit AeroSystems for $4.7 billion in stock and Airbus moved to take on the supplier’s loss-making Europe-focused activities, sending shares in all three companies higher in a rare transatlantic break-up. The near-two-decade independence of the world’s largest standalone aerostructures company ended…

      Read More